1 0 4 7 a r t i c l e s Epigenetic marks on histones are associated with transcriptional processes. For example, trimethylated histone H3 Lys4 is enriched at promoters 1 , and monomethylated H3 Lys4 and acetylated H3 Lys27 (H3K27ac) are enriched at active enhancers 2, 3 . Also, active genes are generally associated with acetylation of histones H3 and H4 on gene bodies 1, 4 . Because some epigenetically marked histones physically interact with specific protein modules, such epigenetic interactions have been hypothesized to participate in the regulation of transcrip tion. Accordingly, synthetic small molecules mimicking epigenetic marks have been developed and have provided a powerful means to investigate the fundamental roles of epigenetic interactions in physio logical and pathological processes of transcription.
a r t i c l e s
Epigenetic marks on histones are associated with transcriptional processes. For example, trimethylated histone H3 Lys4 is enriched at promoters 1 , and monomethylated H3 Lys4 and acetylated H3 Lys27 (H3K27ac) are enriched at active enhancers 2, 3 . Also, active genes are generally associated with acetylation of histones H3 and H4 on gene bodies 1, 4 . Because some epigenetically marked histones physically interact with specific protein modules, such epigenetic interactions have been hypothesized to participate in the regulation of transcrip tion. Accordingly, synthetic small molecules mimicking epigenetic marks have been developed and have provided a powerful means to investigate the fundamental roles of epigenetic interactions in physio logical and pathological processes of transcription.
The bromodomain and extraterminal domain (BET) family proteins 5 , including BRD2, BRD3, BRD4 and BRDT, contain two bromodomains (BDs) 6 , which interact with acetylated histones 7, 8 and other acetylated proteins 9, 10 with varying degrees of affinity. In cells, the BDs are proposed to play a part in recruiting BET fam ily proteins to hyperacetylated chromatin through interaction with acetylated histones 7, 11, 12 . Smallmolecule BET inhibitors such as JQ1 (ref. 13 ) and IBET 14 mimic the acetyl moiety and occlude the BD's acetyllysinebinding pocket, which is unique to the BET family pro teins. Thus, BET inhibitors are highly specific for the BET family proteins. BET inhibitors potently inhibit growth of malignant cells by reducing expression of oncogenes such as Myc [15] [16] [17] and Fosl1 (ref. 18 ). The growing list of cancers that are effectively inhibited by BET inhibitors includes multiple myeloma 15 , acute myeloid leukemia 16 , mixedlineage leukemia 17 , diffuse large Bcell lymphoma 19, 20 , NUT midline carcinoma 13 , lung adenocarcinoma 18 and prostate cancer 10 . Also, BET inhibitors affect immunecell functions 14, 21 and sperma togenesis 22 , and suppress cardiac hypertrophy 23 .
The aim of the present study was to address the role of BRD4 in epigenetic regulation of gene expression. Generally, gene transcription is regulated at the initiation 24 and elongation steps 25, 26 . Transcription initiation begins with the assembly of the preinitiation complex (PIC) on the promoter and is followed by Ser5 phosphorylation of the Cterminal domain (CTD) of Pol II (to form Ser5P Pol II) and by 5′ capping of nascent RNA 27 . The frequency of PIC assembly is con trolled by enhancers. After initiation, a fraction of Pol II is paused within 100 bp downstream of the transcription start sites (TSSs) by the actions of the negative elongation factor (NELF) and DRB sensitivity-inducing factor (DSIF) 26, 28 . To transition to productive elon gation, promoterproximal pausing must be released by the positive elongation factor b (PTEFb), which phosphorylates NELF and DSIF as well as Ser2 of the Pol II CTD (to form Ser2P Pol II) 27, 29 . The Pol II CTD with Ser2P and Ser5P constitutes a binding platform for proteins involved in precursormRNA processing and histone modifications 27 .
BRD4 (refs. 32,35,54) . Some BRD4associated enhancers have been proposed to provide an antipause function for PTEFb on promoter proximal regions via a longrange enhancerpromoter interaction 55 .
In the present study, we set out to address the roles of BRD4 and its bromodomains in the epigenetic regulation of gene expression. We show that BRD4 acts as an elongation factor for Pol II as it traverses acetylated chromatin. We found that BRD4 occupies widespread genomic regions and facilitates elongation of both proteincoding transcripts and eRNAs, in a manner dependent on epigenetic interactions between the BD and acetylated histones. In addition, we found that the BET inhibitor JQ1 antagonizes BRD4 associated eRNA synthesis. Thus, our study suggests that BRD4 is involved in multiple steps of the transcription hierarchy, primarily facil itating transcript elongation both at enhancers and on gene bodies.
RESULTS

JQ1 inhibits initiation and elongation of coding RNA
Transcription is regulated at both the Pol II-recruitment and elon gation steps. To analyze how BRD4 contributes to these distinct transcriptional processes, we used the BET inhibitor JQ1 and mouse fibroblasts that were synchronized by serum starvation and then refed. This allowed the transcriptional initiation of serumresponsive genes to be easily and uniformly captured by genomewide sequencing of the 3′end regions of nascent RNA (Fig. 1a,b and Supplementary Fig. 1 ). JQ1 exhibited a spectrum of inhibition, ranging from a predominant P > 0.05 * * * * * * * * * * * * * * * * * * * * * * **P < 0.01 *P < 0.05 *****P < 0.0005 ****P < 0.001 ***P < 0.005 * * * * * * -200  TSS  +200  +400  10  30  50  70  90  -400  -200  TES  +500 ** * * **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** * *** npg a r t i c l e s inhibition of elongation with little effect on initiation (Fig. 1c, Kctd11 ) to a more general inhibition (Fig. 1c, Tmem41b) . Should JQ1 pre dominantly inhibit the pauserelease action of PTEFb without affect ing the assembly of the PIC, it would be expected to increase the amount of paused transcripts near the TSS. Contrary to this predic tion, metagene profiles of seruminducible and JQ1 sensitive genes showed that JQ1 reduced transcript levels throughout genes, includ ing at the TSS regions (Fig. 1d) . To further dissect the effect of JQ1 at different segments of a gene, we calculated the antagonistic index (the difference divided by the sum, devised to avoid dividing by zero; Fig. 1e ). The index increased from 0.30 near TSSs (corresponding to 46% inhibition) to 0.44 (corresponding to 61% inhibition) in the mid-gene bodies (Fig. 1e) . Thus, JQ1 antagonized both a process regulating PIC assembly and a downstream process involved in pro gressive elongation rather than a typical pauserelease event occurring within 100 bp downstream of the TSS 28 .
JQ1 antagonizes BRD4 and inhibits eRNA synthesis
To understand the basis of the reduced transcription initiation of proteincoding genes by JQ1, we evaluated the role of BRD4 in enhancer activity. Intergenic regions flanking seruminducible genes were enriched for BRD4 and H3K27ac, a marker for active enhancers, and for enhancer elements characterized in multiple mouse 41, 42 and human 53 cell types (Fig. 2a,b and Supplementary Fig. 1c ). These enhancer regions centered around BRD4 peaks were transcribed into noncoding eRNAs, which were bidirectional and were inhib ited by JQ1 in a fashion similar to the inhibition of transcripts of nearby proteincoding genes ( Fig. 2 and Supplementary Fig. 1b,c) .
These observations indicate that, in addition to regulating protein coding genes, BRD4 also regulates transcription of eRNAs, which have been recently reported to be crucial for enhancer activity and gene expression [44] [45] [46] [47] [48] . We further mapped and correlated the genomic distributions of Pol II (pan Pol II, as an indirect marker for eRNA synthesis) and CDK9 (the kinase component of PTEFb) as well as BRD4 at intergenic regions (Figs. 2 and 3 and Supplementary  Fig. 1 ). JQ1 treatment mostly inhibited elongation of the noncod ing transcripts without affecting acetylation of H3 Lys27 and H4 (Supplementary Fig. 1b) . Progression of Pol II and BRD4 was reduced by JQ1, but that of CDK9 was less affected (Fig. 2a, ii a r t i c l e s those associated with both BRD4 and Pol II, was reduced after JQ1 treatment, the number of CDK9associated regions was mostly unaffected (Fig. 3a) . Overall, Pol II recruitment correlated signifi cantly with BRD4 but not with CDK9 ( Fig. 3b and Supplementary  Fig. 2) . Moreover, JQ1 abolished the correlation between Pol II and BRD4 (Fig. 3b) . Consistently with this, Wilcoxon rankscore analysis indicated that the regions associated with both Pol II and BRD4 had significantly higher Pol II read counts than those without BRD4 (Fig. 3c) . These results suggest that BRD4 aids in the synthesis of eRNA. ,e,h,j,k) Spearman's rank correlation analysis between intergenic BRD4 or CDK9 and intergenic Pol II (n = 7,327 intergenic regions grouped by the nearest genes) (b); between intergenic BRD4 or CDK9 and gene-body chromatin RNA-seq read counts (n = 18,354 genes) (d) or gene-body Pol II read counts (n = 15,322 genes) (e); between BRD4 enrichment at distinct sites and the BRD4 dependence in gene expression as defined in g (n = 10,685 genes) (h); and between BRD4 or CDK9 read counts on gene bodies and chromatin RNA-seq read counts (n = 18,354 genes) (j) or Pol II read counts (n = 15,322 genes) (k). P values represent the significance of correlation coefficients (two-tailed). 
We further investigated the contribution of intergenic BRD4 + and CDK9 + regions on the expression of nearby genes. Overall, the inter genic BRD4 enrichment significantly and positively correlated, in a JQ1sensitive manner, with RNAsequencing (RNAseq) read counts ( Fig. 3d and Supplementary Fig. 2 ) and Pol II counts ( Fig. 3e and Supplementary Fig. 2 ) of nearby proteincoding genes. Surprisingly, intergenic CDK9 enrichment inversely correlated with RNAseq and Pol II counts (Fig. 3d,e and Supplementary Fig. 2 ). Whereas the presence of BRD4 at intergenic regions in itself was not associated with increased transcription of nearby genes, BRD4 corecruitment with Pol II significantly boosted transcription (Fig. 3f) . Thus, we found a statistical correlation between intergenic BRD4 and nearby gene expres sion, which might be mediated through enhanced synthesis of eRNA.
Inter- and intragenic BRD4 correlates with gene expression
To specifically address the role of the BRD4 BD interaction with acetylated histones, we constructed a mutant BRD4 (BRD4mBD, carrying a point mutation in each BD) that no longer binds acetylated histones effec tively in vivo, as tested by fluorescent resonance energy transfer (FRET) analysis 7 ( Supplementary Fig. 3 ). We first knocked down endogenous BRD4 with short hairpin RNAs (shRNAs) and then stably reconstituted the cells with shRNAresistant YFPBRD4 (wild type or mBD mutant; Supplementary Fig. 4) . By microarray geneexpression analysis of continuously growing cells, we identified 410 BRD4dependent anno tated genes (downregulated at least 1.5fold by BRD4 knockdown).
After BRD4 reconstitution, we calculated the degree of recovery in gene expression as the recovery ratio (RR) (Fig. 3g) . Whereas wildtype BRD4 restored gene expression by a mean RR of 0.517 ± 0.028 s.e.m., the BD mutated BRD4 was far less efficient (RR, 0.062 ± 0.023; P = 3.4 × 10 −35 by paired twotailed t test (n = 410 genes), representative of two sets of independently reconstituted cells; Supplementary Fig. 4e ). BRD4 dependent genes included those involved in the cell cycle, transcription, DNA repair, phosphorylation and other functions, as indicated by gene ontology annotation (Supplementary Fig. 4e ).
Chromatin immunoprecipitation and deep sequencing (ChIPseq) analysis of YFPBRD4 occupancy in continuously growing cells yielded 37,178 peaks, 28% of which resided at TSS regions, 34% on gene bodies and 38% in intergenic regions. The BRD4dependent gene expression (defined in Fig. 3g ) showed significant correlations with intergenic and gene body-bound BRD4 but not with TSSbound BRD4 (Fig. 3h and Supplementary Fig. 2 ). This suggests that a large fraction of BRD4 present around TSSs may not be directly engaged in transcriptional initiation or early elongation. Furthermore, the intergenic and genebody BRD4 enrichment correlated independently with BRD4dependent gene expression (Fig. 3i) . Moreover, in serum restimulated cells, BRD4 on gene bodies correlated, in a JQ1sensitive manner, with RNAseq ( Fig. 3j and Supplementary Fig. 2 ) and Pol II read counts ( Fig. 3k and Supplementary Fig. 2 ) on gene bodies. In con trast, the weaker correlation between genebody CDK9 and RNAseq or Pol II read counts on gene bodies was not sensitive to JQ1 (Fig. 3j, 
BRD4 BD is not required for loading BRD4 and P-TEFb at TSSs
Next, we selected representative BRD4dependent genes, Myc and Klf4, and tested the role of the BDs in transcript elongation. BRD4 knockdown or JQ1 treatment under a continuous growth condition reduced total transcript levels of Myc and Klf4 by approximately 50% (Fig. 4a,b and Supplementary Fig. 5a ). This suggests that the con tribution of BRD4 to gene expression of Myc and Klf4 is substantial, albeit not exclusive, in nontransformed cells. In BRD4knockdown cells, wild type YFPBRD4 effectively rescued Klf4 and Myc expres sion, whereas YPFBRD4mBD was ineffective (Fig. 5a ). Transcript elongation on these genes was clearly inhibited by JQ1 ( Fig. 4c ; Pol II progression in Supplementary Fig. 5b ).
ChIP and quantitative PCR (ChIPqPCR) and ChIPseq assays revealed that BRD4 is widely distributed over the Klf4 and Myc genes ( Fig. 4d and Supplementary Fig. 5c,d) . Despite the lack of rescue activity on gene expression, we detected substantial amounts of BRD4 mBD around TSSs and the proximal portions of gene bodies ( Fig. 4d  and Supplementary Fig. 5c ). Similarly, JQ1 did not greatly reduce the amount of BRD4 around TSSs (Fig. 4e) . Also, the amount of PTEFb (CDK9) was comparable in BRD4mBD-reconstituted cells or JQ1 treated cells and wildtype BRD4 or mocktreated cells, respectively (Fig. 4f,g and Supplementary Fig. 5e ). These data indicate that BD mediated interactions with acetylated nucleosomes (and possibly other proteins) are not essential for loading BRD4 or PTEFb at the TSSs, especially at the Klf4 TSS region that is devoid of nucleosomes and acetylated histone marks (Fig. 4h,i) . Given that BRD4 interacts with several components of Mediator 32, 35, 54 , BRD4 may be recruited by Mediator complexes, which are present around the Klf4 and Myc TSS regions (data not shown). In contrast, this JQ1resistant recruitment of BRD4 cannot be accounted for by indirect recruitment from distant enhancers such as superenhancers, from which BRD4 dissociates at low concentrations of JQ1 (ref. 53 ).
BRD4 facilitates in elongation through nucleosomes in vitro
For BRD4dependent gene expression, therefore, the function of BDs is crucially required at a step beyond the recruitment of PTEFb and BRD4 itself. Accordingly, we considered the possibility that BRD4 actively participates in the transcriptelongation process. BRD4 possesses an intrinsic kinase activity and may complement PTEFb in Pol II phosphorylation on Ser2 (ref. 56 ). However, the BRD4 kinase activity itself does not require the function of BDs 56 , and thus it does not account for the BDdependent postrecruitment function of BRD4.
It was previously reported that BRD2, another BET protein, pos sesses a histonechaperone activity and aids in Pol II elongation in vitro 11 , thus raising the possibility that BRD4 may also possess similar activity. Thus, we first confirmed the histonechaperone activity of BRD4 by plasmid supercoiling assays (Fig. 5a) and pro ceeded to test in vitro transcription activity. BRD4 allowed Pol II to transcribe through nucleosomes in a manner dependent on histone hyperacetylation (Fig. 5b,c and Supplementary Fig. 6 ). Importantly, JQ1 specifically inhibited the activity of BRD4 but not that of the FACT complex (Fig. 5d) . Because only nucleosomes were hyperacetylated in these experiments, that would exclude the possibility that other potential protein interactions with BRD4 bromodomains are involved in this process. Thus, BRD4 assists in Pol II transcription through hyperacetylated nucleosomes via its histonechaperone activity, which is dependent on its BD-acetylated histone interactions.
BRD4 facilitates elongation in a BD-dependent manner in vivo
Next, in order to test whether BRD4 assists in the passage of elon gating Pol II complexes in vivo, and whether BRD4 functions inde pendently of its PTEFb interaction in this process, we expressed short forms of BRD4 (BRD4short and its mBD mutant) lacking the Cterminal PTEFb-interacting domain 37 % of all histone H4 ( Supplementary Fig. 4 ). This short form 5,57 essentially corresponds to the human isoform C, which lacks the DNA damage-modulating activity reported for isoform B 58 . Strikingly, BRD4short but not BRD4shortmBD rescued expres sion of Klf4, Myc and many other genes in BRD4knockdown cells (Fig. 6a) . ChIP analysis revealed that both forms of short BRD4 proteins were bound to the nucleosomedepleted TSS region of Klf4 at similar levels but that they were distributed differently along the highly acetylated gene body (Fig. 6b) . Nascent RNA-seq analysis showed that transcripts extended more extensively toward the tran scription end site (TES) with expression of wildtype BRD4short than with BRD4shortmBD ( Fig. 6c; Supplementary Fig. 7a for Myc). We further verified this by quantitative reversetranscription PCR (qRTPCR) analysis of nuclear runon chromatinRNA samples ( Fig. 6d; Supplementary Fig. 7b for Myc). We further examined the progression of Pol II along gene bodies. We detected considerable lev els of Ser2P Pol II, which presumably represent an elongating form in BRD4knockdown cells, and used these levels to monitor the progres sion of Pol II by ChIP assays. Consistently with the transcript analyses, the distribution of Ser2P Pol II was shifted toward and beyond the TESs in cells reconstituted with YFPBRD4short compared with cells expressing the mBD mutant ( Fig. 6e,f; Supplementary Fig. 7c for Myc). The distribution of Ser5P Pol II was also shifted by BRD4short in a similar manner to that of Ser2P Pol II (Fig. 6g) , thus confirm ing that the observed changes were due to altered distribution of Pol II. No clear difference in nucleosome deposition was apparent among these cells, as assessed by histone H3 deposition ( Fig. 6h;  Supplementary Fig. 7d for Myc). These results collectively support the idea that BRD4short facilitates the progression of Pol II along the gene body via its histonechaperone activity, depending on the BD acetylated histone interaction in vivo. Although the possibility that other acetylated proteins may interact with BDs in vivo cannot be ruled out, it would be in addition to but not instead of the interaction with acetylated histones.
BRD4 interacts with Pol II elongation complexes in vivo
We reasoned that BRD4 may have traveled together with the Pol II elongation complexes. When we blocked transcription by actino mycin D (Act D), the BRD4 distribution was dramatically reduced (Fig. 7a) , although acetylation marks on histones H3 and H4 were unchanged or even increased (Fig. 7b,c) . This indicates that interac tions with acetylated histones are not necessarily sufficient to recruit BRD4 on gene bodies and that ongoing transcription may also be required. Thus, the passage of Pol II complexes and BRD4 along the gene body and the interaction of BRD4 with acetylated nucleosomes are mutually dependent to some degree. 
npg a r t i c l e s
To document a physical association of BRD4 with actively elongat ing Pol II complexes, we labeled elongating transcripts with 5bromo UTP (BrUTP) in a mild nuclear runon reaction and sequentially immunoprecipitated the transcripts associated with native protein-RNA complexes with antibodies against YFP (for YFPBRD4 or YFPBRD4short) and bromodeoxyuridine (BrdU) (for labeled RNA) (Fig. 7d) . BRD4 or BRD4short was associated with elongating Klf4 and Myc transcripts, as shown by qRTPCR ( Fig. 7e and Supplementary  Fig. 8b) or RNAseq (Fig. 7f,g and Supplementary Fig. 8c ). These results indicate that actively transcribing Pol II complexes are associ ated with BRD4 in vivo.
DISCUSSION
In the present study, we show that BRD4 functions as a histone chap erone, using its interaction with acetylated histones and assisting in the passage of Pol II through hyperacetylated nucleosomes (Fig. 8) . This BDdependent process represents a mechanism that was directly antagonized by BET inhibitors (Fig. 8) . Our results demonstrate that the chaperonemediated activity of BRD4 facilitates transcript elonga tion both at enhancers and within proteincoding genes. The apparent inhibition of transcription initiation by JQ1 that we observed suggests that BRD4 may also be associated with transcription initiation of proteincoding genes, possibly via an eRNAmediated mechanism. Thus BRD4 assisted, and BET inhibitors antagonized, transcription regulatory mechanisms at multiple levels.
The proposed model of histonechaperone activity is distinct from the conventional model 12, 49, 53, 55 , in which BRD4 functions as an adaptor to recruit PTEFb and releases Pol II from pausing near the TSS. In the present model, BRD4 is also a direct effector that functions at enhancers and on gene bodies. The two models are not mutually exclusive and may well cooperate. Several lines of evi dence support the histone chaperone-mediated mechanism of BRD4: (i) BRD4dependent gene expression correlated with the presence of BRD4 in intergenic regions and on gene bodies but not at TSSs; (ii) the presence of PTEFb did not correlate well with Pol II reads or RNA seq reads; (iii) in BRD4knockdown cells, exogenous expression of a short form of BRD4, which does not interact with PTEFb, was able to rescue the expression of BRD4dependent genes; (iv) the BD mutant of fulllength BRD4, which maintains the ability to interact with PTEFb, failed to rescue gene expression even when both proteins were loaded at the TSS; and (v) BRD4 allowed Pol II to transcribe through hyperacetylated nucleosomes in a defined in vitro assay, which was performed in the absence of PTEFb.
Mutagenesis of the BD in BRD4 provided a powerful tool to study the function of this domain in vivo. For a subset of BRD4dependent genes, including Klf4 and Myc, the primary function of the BDs was not to load BRD4 at TSSs but to facilitate transcript elongation. We moni tored the elongation process by three different methods. In addition to conventional Pol II ChIP analysis, we also mapped nuclear runon transcripts to monitor the positions of Pol II without relying on ChIP antibodies. Furthermore, we directly monitored the positions of the elongating ends of nascent transcripts. The results were all consistent and suggested that, under our experimental conditions, the essential role of BRD4 BDs in gene expression is to help elongate transcripts.
In addition to BRD4, BRD2 and BRD3 also possess histone chaperone activity and have the ability to facilitate transcript elonga tion through nucleosomes in vitro. Furthermore, BRD2 and BRD3 are also associated with acetylated nucleosomes in vivo and participate in a r t i c l e s gene expression 7, 11, 59 . Thus the histone chaperone activity could be the primary target of BET inhibitors. This is in line with previous reports, in which individual knock downs of BRD2, BRD3 and BRD4 mimicked actions of BET inhibitors 14, 19, 20 . Although BRD4 is also known to possess kinase activity for Pol II Ser2, this activity is not the target of BET inhibitors 56 . Ser2P on Pol II, whose formation can also be catalyzed by PTEFb, creates a platform to recruit factors involved in RNA processing such as splicing and 3′end processing 27 . In contrast, the histonechaperone activity of BRD4 facilitates the passage of Pol II through nucleosomes. Thus, BRD4 appears to have distinct functions that probably cooperate in vivo.
In order to address the passage of BRD4 along the gene body, we devised a sequential immunoprecipitation method, referred to as runon RNA immunoprecipitation and deep sequencing (runon RIPseq) to pull down native Pol II elongation complexes contain ing both nascent RNA and BRD4. Our results showed that actively elongating transcripts from Myc and Klf4 genes coimmunoprecipi tated with BRD4, suggesting that BRD4 was physically associated with elongating Pol II complexes. This assay may be helpful to further dissect Pol II elongation complexes because many other elongation factors may associate with Pol II as it traverses gene bodies.
BRD4 can be found throughout the genome. In the present study, we noted a significant correlation between BRD4dependent gene expression and the presence of BRD4 in intergenic regions and on gene bodies but not at TSS regions. We suggest that BRD4 is loaded at the TSSs of both active and inactive genes. In BRD4dependent active genes, the loaded BRD4 would then move downstream with Pol II complexes so that the gene body/TSS ratio of BRD4 would increase in proportion to gene activity. That ongoing transcription was required for BRD4 to move along the gene body suggests that BRD4 by itself is not sufficient to drive transcription. Once tran script elongation has been initiated, BRD4 facilitates the passage of Pol II through nucleosomes in a manner dependent on the state of nucleosome acetylation. However, neither Pol II-complex assembly nor nucleosome acetylation is directly regulated by BRD4. These addi tional requirements may account, at least in part, for the relatively small statistical correlations observed between the amount of BRD4 and transcriptional output (Fig. 3) .
At enhancers, BRD4 is associated with eRNAs, which are bidirec tional and efficiently inhibited by JQ1. The similar association has recently been observed for estrogen receptor-dependent enhancers 60 . The present correlation analysis suggests that BRD4 assists in eRNA synthesis, which may be associated with enhancer function. The present analysis further suggests that it is the eRNA, but not BRD4 itself or PTEFb, that is statistically associated with nearby gene expression. Thus, BRD4 at enhancers may influence the expression of associated target genes indirectly through its effect on eRNA synthesis. It is worth noting, however, that the observed inhibition of transcription initiation by JQ1 could also suggest a more direct role for BRD4 in the initiation step.
In summary, the present study reveals a role of BRD4 in transcript elongation at enhancers and gene bodies. The elongationfacilitating function of BRD4 on gene bodies depends on the function of the BD after the initial recruitment of BRD4 and on its physical association with Pol II complexes. This function is most probably accounted for by its BDdependent histonechaperone activity. Whereas small molecule drugs targeting epigenetic interactions are designed to interfere with factor recruitment, BET inhibitors act more directly by occluding a functional interface of BRD4. As more epigenetic drugs enter into clinical trials, the roles of each epigenetic interaction must Figure 8 A model depicting the interdependence between the passage of Pol II elongation complexes through nucleosomes and acetyl-histone binding of BRD4 at enhancers and within protein-coding genes. BRD4 contributes to the progression of the elongation complexes via its histone-chaperone activity depending on its interaction with hyperacetylated nucleosomes. The BET-bromodomain inhibitor JQ1 occludes the acetyl-histone-binding pockets of the BRD4 bromodomains, disabling the elongation-facilitating activity of BRD4. 
On the basis of the present study, BET inhibitors may pref erentially target hyperacetylated genes with active enhancers.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray and deepsequencing (ChIPseq, nas cent RNA-seq and runon RIPseq) data have been deposited in the Gene Expression Omnibus database under accession codes GSE56370 and GSE58731, respectively. 
ONLINE METhODS
Cells. NIH3T3 cells were cultured in DMEM supplemented with donor bovine serum and antibiotics. HEK293T and the PlatinumE retroviralpackaging cell line (Cell Biolabs) were cultured in DMEM supplemented with FBS and antibiotics.
Expression and knockdown plasmid constructs. Retroviral backbone vectors for protein expression (pMSCVpuro; Clontech) and knockdown (pSRneo; Oligoengine) were purchased. pSRneoshBRD4 and pSRneo shCont were as previously described 12, 35 . Mouse BRD4 cDNA was as previ ously described 61 . BRD4short cDNA was produced by PCR. Point mutations of bromodomains were created by mutagenesis with the QuikChange II sitedirected mutagenesis kit (Stratagene). All the BRD4 constructs described in the present study contained nucleotide substitutions around the target site of BRD4 shRNA 12, 35 to confer resistance to BRD4 shRNA while keeping the amino acid coding unchanged at the corresponding region.
BRD4 knockdown and reconstitution. NIH3T3 cells were sequentially infected with shRNA retroviruses and YFPBRD4-expressing retroviruses. Virus infection was carried out in the presence of polybrene according to a standard method 12 . The transduced cells were selected with G418 and puromycin.
Live-cell FRET analysis. For FRET analysis, 8 × 10 5 HEK293T cells seeded on 6cm dishes were transfected with expression vectors for a CFPfusion protein (4 µg) and a YFPhistone protein (0.2 µg) with FuGene6 (Roche). Live cells were harvested 24-48 h after transfection and were immediately analyzed on a CyAn ADP (Beckman Coulter) as described previously 7 , with some modifications. Excitation lasers and filters for detection channels were a solidstate violet laser (405 nm) and a 450/50nm bandpass filter for CFP; an argon laser (488 nm) and a 546/10nm bandpass filter for YFP; and a 405nm solidstate violet laser and a 546/10nm bandpass filter for FRET. All three signals were detected from the same individual cells by sequential illumination with the 488nm and 405nm lasers. Results were analyzed with Summit software v4.3.1, and compensation values for spillover signals were determined with the data from singly trans fected cells. Signals from individual cells were grouped into a matrix of 28 (CFP signals) × 32 (YFP signals) grids, and mean FRET signals representing those grids were displayed by threedimensional surface plots with JMP software (SAS Institute).
In vitro chromatin assembly and transcription from chromatin templates. Chromatin was assembled on the pG5MLP transcription template, which con tained five GAL4binding sites upstream of the adenovirus major late promoter and a 390bp Gless cassette. For assembly, 4 µg of pG5MLP DNA was incubated with 4 µg of the purified core histones (either hypoacetylated or hyperacetylated), 40 µg BSA, 500 ng GAL4AD, 100 ng RSF, 3 mM ATP, 30 mM creatine phosphate (Sigma), 0.2 µg creatine phosphokinase (Sigma) in 10 mM HEPESKOH, pH 7.6, containing 5 mM MgCl 2 , 50 mM KCl, 0.2 mM EDTA and 5% (v/v) glycerol, as previously described 11 . Core histones (hypoacetylated and hyperacetylated) were purified from HeLa cells as previously described 62 . Quantification of histone posttranslational modifications in the hypoacetylated and hyperacetylated his tone preparations was performed by MS as previously described in detail 63 . The purification of RSF and GAL4AD was performed as previously described 11, 64 . Transcription reactions contained 200 ng of chromatinassembled pG5ML (± 200 ng of FACT or BRD4 as indicated) with 10 ng TFIIA, 10 ng TBP, 10 ng TFIIB, 10 ng TFIIF, 50 ng TFIIE, 50 ng TFIIH and 100 ng RNA polymerase II, 3 mM each of ATP and CTP, 0.03 mM UTP, 12 U of RNasin (Promega) and 5 µCi/reaction [α 32 P]UTP (800 Ci/mmol PerkinElmer) in 10 mM HEPESKOH, pH 7.9, con taining 50 mM KCl, 6 mM MgCl 2 and 1.25% PEG (w/v) (average MW 8000), and were incubated at 30 °C for 1 h (ref. 11). Transcription was stopped with 20 mM EDTA containing 200 mM NaCl, 1% SDS (w/v) and 25 µg glycogen, and the Gless transcripts were then digested with 50 U RNase T1 (Roche) for 30 min at 30 °C. After deproteinization, the transcripts were run on 6% polyacrylamide gels con taining 8 M urea in 1× TBE (0.09 M Trisborate, pH 7.5, and 2 mM EDTA). For JQ1 inhibition, 200 ng of FACT or BRD4 was incubated with 60 µM of JQ1 in DMSO or DMSO alone (vehicle) for 1 h before being added to the assay. The purification of FACT, BRD4, TFIIA, TFIIB, TBP, TFIIF, TFIIE, TFIIH and RNA polymerase II was performed as previously described 11, [65] [66] [67] .
Supercoiling assay. 6 pmoles of hyperacetylated core histones from HeLa cells were preincubated with 0, 1, 2.5, or 5 pmoles of BRD4 in 10 µL assembly buffer (10 mM TrisHCl, pH 7.6, 100 mM KCl, 1 mM MgCl 2 , 1 mM DTT and 0.05 mg/ml BSA) for 30 min at 30 °C. In a parallel reaction, 1 pmole of super coiled pFASTBAC1 plasmid was relaxed with 50 ng of Drosophila topoisomerase I fragment ND423 in 10 µL of assembly buffer containing 5 mM KCl, at 30 °C for 30 min. 1 µl of the topoisomerase I-relaxed circular DNA (100 fmoles) was added to each histone/BRD4 mixture, and the reaction was incubated at 30 °C for 2.5 h. The assembly reaction was stopped by addition of an equal volume of stop buffer (10 mM EDTA, pH 8.0, 0.05% SDS and 1 µg/µL glycogen), and 2.5 µg proteinase K was added. The mixture was further incubated for 30 min at 45 °C. DNA was subsequently isolated with phenol:chloroform extraction and ethanol precipitation, resolved on an 0.8% agarose gel and visualized by ethidium bromide staining. ND423 was kindly provided by J. Kadonaga (UCSD).
Nuclear extracts. Nuclear extracts were prepared as previously described 68 .
qRT-PCR of total RNA. Expression levels of genes were quantified by realtime PCR with the Fast SYBR Green Master Mix and genespecific primers on a 7500 Fast RealTime PCR System (Applied Biosystems).
Microarray. Amplification and labeling of cDNA and hybridization were carried out at Precision Biomarker Resources (Evanston, Illinois, USA). Biotinylated cDNA was generated from 150 ng total RNA. 5 µg of fragmented cDNA was hybridized to expression microarrays (Mouse Exon 1.0 ST array, Affymetrix). Affymetrix Expression Console software was used to generate expression values from the CEL files with the RMA expression measure. ChIP-qPCR and ChIP-seq. Cells (2 × 10 7 ) were crosslinked with 1% formal dehyde and sonicated. A fraction of the lysate was kept aside as input control. For ChIPqPCR, lysates typically corresponding to 2 × 10 6 cells were immuno precipitated with Protein A-coupled magnetic beads, and beads were washed as previously described 69 . Recovered DNA was subjected to qPCR with locus specific primer pairs. The results were normalized to the input DNA. For ChIPseq analysis, 2 × 10 7 cells were subjected to an IP, and 3-30 ng of DNA was recovered, depending on antibodies. Libraries compatible with the Illumina plat form were prepared according to the manufacturer's protocol and were sequenced by an Illumina GA analyzer or a HiSeq 2000. For GAgenerated reads, reads were mapped to the mouse genome (mm9), and peaks were called via CisGenome as described previously 69 Preparation of nascent-chromatin-RNA libraries. Chromatinassociated RNA was isolated as previously described 24 , with modifications. Briefly, cells (5 × 10 6 ) were scraped in swelling buffer (10 mM TrisHCl, pH 7.5, 2 mM MgCl 2 , 3 mM CaCl 2 and RNaseOUT), and the cell pellets were lysed in sucrose lysis buffer (5 mM TrisHCl, pH 7.5, 1 mM MgCl 2 , 3 mM CaCl 2 , 0.5% NP40, 0.25 M sucrose and RNaseOUT). The nuclear pellets were resuspended in chromatin wash buffer (10 mM TrisHCl, pH 7.5, 150 mM NaCl, 7.5 mM MgCl 2 , 0.1 mM EDTA, 0.5 M urea, 0.5% NP40, 0.5 mM DTT and RNaseOUT), vor texed briefly, incubated on ice for 1 min and spun. Chromatinassociated RNA was extracted from the nucleoplasmic supernatant according to the TRIzol npg protocol, treated with DNase I (10 units), and reextracted with acid phenol/ chloroform and chloroform/isoamyl alcohol.
The chromatinassociated RNA (1 to 2 µg) was depleted of rRNA with RiboMinus Eukaryote Kit for RNAseq (Invitrogen). To degrade uncapped RNAs, the RNA preparation was sequentially treated with 20 units of RNA 5′ polyphos phatase (Epicentre) and 1 U of Terminator 5′phosphate-dependent exonuclease (Epicentre), each followed by phenol/chloroform and chloroform/isoamyl alcohol extraction and ethanol precipitation. The 3′hydroxyl group of the nascent RNA was ligated with a preadenylated RNA 3′ adaptor (TruSeq Small RNA Sample Preparation kit, Illumina: TGGAATTCTCGGGTGCCAAGG) with T4 RNA ligase 2, truncated (NEB, 200 U) for 3 h at 25 °C. Fragmentation of the RNA was per formed as previously described 74 in 200 mM NaOH on ice for 20 to 30 min (most fragments <200 nt, checked by Agilent Bioanalyzer), and this was followed by neutralization with an equal volume of 1 M TrisHCl, pH 6.8. The RNA was puri fied through BioSpin P30 RNasefree columns (BioRad). The cap structure was removed with 10 U of tobacco acid pyrophosphatase (Epicentre). The 5′ ends of the hydrolyzed RNA fragments were phosphorylated with 30 U of T4 polynucleotide kinase, 3′ phosphatase minus (NEB) and 1 mM ATP. Ligation of RNA 5′ adaptor (TruSeq Small RNA Sample Preparation kit, Illumina: GUUCAGAGUUCUAC AGUCCGACGAUC), reverse transcription and PCR with multiindex primers were performed according to the Illumina protocol.
Run-on qRT-PCR. Nuclear runon labeling of RNA with BrUTP and the purifi cation, fragmentation and immunoprecipitation (twice with antiBrdU antibody) of the labeled RNA were performed according to the GROseq protocol 74 , with 5 × 10 6 cells per transduced NIH3T3 cell type. cDNA was made from the immunoprecipitated RNA fragments with random hexamers, and qPCR was performed with specific primers with the Fast SYBR Green system. Run-on labeling. NIH3T3 cells transduced to express YFPBRD4 or YFP BRD4short (5 × 10 6 cells) were swelled on ice for 5 min with swelling buffer (described above). Cells were scraped, centrifuged and resuspended in 5 ml of swelling buffer. 5 ml of 2× lysis buffer (10 mM TrisHCl, pH 7.5, 2 mM MgCl 2 , 3 mM CaCl 2 , 1% NP40, 20% glycerol, RNaseOUT and protease inhibitors) was added, and cells were lysed. The nuclei were resuspended in 0.2 ml of 1× lysis buffer. 10 ml of 1× lysis buffer was added, and the nuclei were centrifuged and resuspended in 0.2 ml of freezingstorage buffer (50 mM TrisHCl, pH 8.0, 5 mM MgCl 2 , 0.1 mM DTT, 40% glycerol, RNaseOUT and protease inhibitors). After being washed in the same buffer, the nuclei were resuspended in 0.1 ml freezing storage buffer and were frozen in ethanol dry ice. The nuclei were thawed on ice and mixed well with 0.1 ml of 2× nuclear runon master mix without sarkosyl (10 mM TrisHCl, pH 8.0, 300 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 0.5 mM ATP, 0.5 mM GTP, 0.00233 mM CTP, 0.5 mM BrUTP, RNaseOUT and protease inhibitors) by gentle but thorough pipetting, repeated at least 15 times. The run on mixture was incubated in a 30 °C water bath for 5 min with occasional shaking and then placed on ice.
Run
Native RNA immunoprecipitation. The runon nuclei (0.2 ml) were mixed with 0.3 ml of digestion buffer (30 mM TrisHCl, pH 7.5, 7 mM MgCl 2 , 1.7 mM CaCl 2 , RNaseOUT and protease inhibitors), and digested with 200 U DNase I for 30 min on ice. The reaction was added with 8 µL of 0.5 M EDTA and 0.5 ml of RIP BindAjust Buffer (10 mM TrisHCl, pH 7.5, 238 mM NaCl, 0.35% NP40, RNaseOUT and protease inhibitors). Insoluble materials were removed by centrifugation, and the supernatant was combined (1 ×10 7 cells equivalent per sample). For preclearance of samples, four microcentrifuge tubes containing Dynabeads Protein A (1.5 mg per tube) were prepared per sample. In parallel, antiYFP or IgG Dynabeads were prepared. For this, six tubes containing pre washed Dynabeads Protein A (1 mg each) and 2 µL of antiGFP antibody (Abcam ab290) or normal rabbit IgG were prepared per sample. Before use, these beads were washed twice in 1 ml RIP wash buffer (20 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.2% NP40, RNaseOUT and protease inhibitors), and this was followed by incubation in RIP blocking buffer (1 mg/ml BSA, 0.1% PVP, 20 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.2% NP40, RNaseOUT and protease inhibitors) for 2 h with rotation at 4 °C. The Dynabeads Protein A beads for preclearance were washed twice with RIP wash buffer, and each of the four tubes was added with 1/4 of the samples. After 2 h of rotation at 4 °C, the beads were separated on the magnet, and the supernatants were collected and combined as a precleared sample. The antiYFP Dynabeads were washed twice with RIP wash buffer, and each of the six tubes was added with 1/6 of the precleared sample. The tubes were rotated for 16 h at 4 °C, after which the beads were washed five times with 1 ml of RIP wash buffer. After the final wash, the beads from three tubes were combined and resuspended in 0.1 ml 1× DNase I buffer, into which 4 µL of DNase I was added and gently mixed. After 15min incubation at room temperature, 1.6 µL of 0.5 M EDTA, 1 µL of 10% SDS and 1.5 µL of 20 mg/ml proteinase K were added, and the tubes were incubated for 30 min at 55 °C. After cooling of samples to room temperature, 0.9 ml TRIzol was added. The RNA pellet was resuspended in 6.5 µL of water per tube, and the RNA from two tubes was combined.
Adaptor ligation and BrU-RNA immunoprecipitation. The precipitated RNA was ligated with a preadenylated RNA 3′ adaptor (Illumina) with T4 RNA ligase 2, truncated (NEB, 200 U). The RNA was fragmented by base hydrolysis in 0.2 M NaOH, neutralized and immunoprecipitated with antiBrdU agarose beads according to the GROseq protocol 74 , except that buffered phenol/chloroform, pH 8.0, was used instead of acid phenol/chloroform. The 5′cap structure was removed with tobacco acid pyrophosphatase (Epicentre, 10 U). The 5′ ends of the hydrolyzed RNA fragments were phosphorylated with T4 polynucleotide kinase (NEB, 30 U) and 1 mM ATP. Ligation of RNA 5′ adaptor (Illumina), reverse tran scription and PCR with multiindex primers were performed according to the Illumina protocol, and samples were subjected to massively parallel sequencing. For qRTPCR analysis, cDNA was made with random hexamers, and qPCR was performed with specific primers with the Fast SYBR Green system. Chromatin RNA-seq data analysis. RNAseq data were generated with an Illumina HiSeq 2000 system. Raw sequencing data were processed with CASAVA 1.8.2 to generate FastQ files. Reads of sequentially varying length were mapped to the mouse genome mm9, and the 5′most 29 bases were identified as giving the maximum number of genomic matches. The 29 base reads were thus used throughout this study. Reads aligned to ribosomal DNA were first removed. The ribofree reads were then mapped to the mouse genome mm9 with Bowtie 0.12.8 (uniquely mapped only, allowing two mismatches). Strandspecific bed files and bigWig files were made with BEDtools 75 , the UCSC genome browser tool bedGraphToBigWig and in house-developed Python scripts. Partek Genomic Suite 6.6 was used to calculate exonmappedreadsonly reads per kilobase per million mapped reads (RPKMs), and allreads (intronmapped reads also included) RPKMs. For a list of individual genes of interest, strand specific bed files were used to generate strandspecific readdensity profiles around the TSSs (±500 base, 100 base bin), gene bodies (10% bin) and TESs (±500 base, 100 base bin), with an in house-developed Python program. To study the nascent RNA-seq data around BRD4 peaks, Homer was used to call the peaks and to assign peaks as either genic or intergenic. The nascent RNA-seq readdensity profiles were then generated with Homer around the BRD4 peak centers (± 2,000, 200 base bin). The readdensity heat map was made with Partek Genomic Suite 6.6.
Metagene profiling. We first generated a list of genes that were upregulated by serum by 1.5 fold or more, as compared with those in serumstarved cells, from total genebody read counts. From this, we generated the second list, contain ing genes whose total read counts were inhibited by JQ1 by 1.5 fold or more. By visual inspection on a genome browser, we excluded the genes that met the following criteria: (i) genes smaller than 2 kb, (ii) genes overlapping with other genes including RNA genes, (iii) genes not separated from other genes including RNA genes by at least 0.5 kb, (iv) genes over which RNAseq reads from other genes spread, (v) genes whose RNAseq reads were not detected at annotated TSSs and (vi) genes with sharp RNAseq read spikes of great intensity at regions other than TSSs.
The scaled metagene profile was generated as previously described 76 . The region spanning from 500 bp downstream of the TSS to 500 bp upstream of the TES was defined as the 'scaled gene body' region. Normalized profiles were npg generated for each gene by division of the subregional read counts in each experi mental condition by the total read counts of the gene (from 200 bp upstream of the TSS to the TES), obtained with the serumstarved and vehicletreated cells (Supplementary Fig. 1a) or the serumstimulated and vehicletreated cells (Fig. 1d) . The antagonistic index was calculated as shown in Figure 1e in order to avoid division by zero.
Statistics. JMP 10 software (SAS Institute) was used for computation of the Spearman rank correlation coefficient and the KruskalWallis test on the joint Wilcoxon ranking, performed with Dunn's all pair comparison procedure.
